Key Dates

Related Announcements

• August 29, 2023 - Broadening Opportunities for Computational Genomics and Data Science Education (UE5 – Clinical Trial Not Allowed). See NOFO RFA-HG-23-002.

Issued by

National Institute on Drug Abuse (NIDA)

Purpose

The purpose of this notice of participation is to inform the extramural community that the National Institute on Drug Abuse (NIDA) is participating in RFA-HG-23-002, Broadening Opportunities for Computational Genomics and Data Science Education (UE5 – Clinical Trial Not Allowed).

The following changes in RFA-HG-23-002 reflect NIDA's participation:

Part 1. Overview Information,

Components of Participating Organizations

Currently reads:

National Human Genome Research Institute (NHGRI)
National Cancer Institute (NCI)

Modified to read (in Bold Italic):

National Human Genome Research Institute (NHGRI)
National Cancer Institute (NCI)

National Institute on Drug Abuse (NIDA)

Currently read:

Assistance Listing Number(s)

93.172, 93.398

Modified to read (in Bold Italic):

Assistance Listing Number(s)

93.172; 93.398; 93.279

Part 2. Full Text of Announcement

Section I. Funding Opportunity Description

Currently read:

The overarching goal of this UE5 program is to support educational activities that encourage individuals from diverse backgrounds, including those from groups underrepresented in the biomedical and behavioral sciences, to pursue further studies or careers in computational genomics and data science research.

This NOFO will support educational activities with a primary focus on:

• Curriculum or Methods Development

Specifically, this NOFO will support the development of undergraduate and master’s degree-level classroom content, and hands-on as well as online exercises related to computational genomics, data science, cloud computing, or a combination of these topics, tailored towards students attending institutions with a mission to serve historically underrepresented populations in biomedical research as described below in Section III.

Modified to read (in Bold Italic):

To accomplish the stated overarching goal, this funding opportunity will support creative educational activities with a primary focus on: 

• Curriculum or Methods Development 

Specifically, this UE5 will support the development of undergraduate and master’s degree-level classroom content, and hands-on as well as online exercises related to computational genomics, data science, cloud computing, or a combination of these topics, tailored towards students attending institutions with a mission to serve historically underrepresented populations in biomedical research. 

NIDA supports innovative research addressing critical issues of neuroscience, genetics, behavior, prevention, treatment, epidemiology, etiology, health services, HIV/AIDS, and co-occurring opportunistic infections (e.g., viral hepatitis C, tuberculosis, sexually transmitted infections) associated consequences in substance using populations, medication development, or other research areas relevant to substance use disorder. NIDA encourages applications focused on educational activities that are related to computational genomics, data science, and/or cloud computing relevant to addiction training and research.

Part 2. Section VII. Agency Contacts 

Scientific/Research Contact(s)

Currently read:

Shurjo K. Sen, Ph.D.
National Human Genome Research Institute (NHGRI)
Telephone: 301-827-7028
Email: sensh@mail.nih.gov 
 

Modified to read (in Bold Italic):

Shurjo K. Sen, Ph.D.
National Human Genome Research Institute (NHGRI)
Telephone: 301-827-7028
Email: sensh@mail.nih.gov

Nastaran Zahir, Ph.D.
National Cancer Institute (NCI)
Telephone: 240-276-6333
Email: nas.zahir@nih.gov

Susan N. Wright, PhD
National Institute on Drug Abuse (NIDA)
Division of Neuroscience and Behavior (DNB)
Phone: (301) 402-6683
Email: susan.wright@nih.gov

Financial/Grants Management Contact(s)

Currently read:

Donna Morris
National Human Genome Research Institute (NHGRI)
Telephone: 301-827-2745
Email: donna.morris@nih.gov  

Crystal Wolfrey
National Cancer Institute (NCI)
Telephone: 240-276-6277
Email: crystal.wolfrey@nih.gov

Modified to read (in Bold Italic):

Donna Morris
National Human Genome Research Institute (NHGRI)
Telephone: 301-827-2745
Email: donna.morris@nih.gov

Crystal Wolfrey
National Cancer Institute (NCI)
Telephone: 240-276-6277
Email: crystal.wolfrey@nih.gov

Pam Fleming
National Institute on Drug Abuse (NIDA)
Telephone: 301- 480-1159
Email: pfleming@nida.nih.gov

All other aspects of NOFO remain unchanged.

Inquiries

Please direct all inquiries to:

Susan N. Wright, PhD
National Institute on Drug Abuse (NIDA)
Division of Neuroscience and Behavior (DNB)
Phone: (301) 402-6683
Email: susan.wright@nih.gov